Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

INBS vs QDEL

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
INBS
Intelligent Bio Solutions Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$3M
5Y Perf.-99.9%
QDEL
QuidelOrtho Corporation

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$733M
5Y Perf.-94.0%

INBS vs QDEL — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
INBS logoINBS
QDEL logoQDEL
IndustryMedical - Diagnostics & ResearchMedical - Instruments & Supplies
Market Cap$3M$733M
Revenue (TTM)$4M$2.66B
Net Income (TTM)$-11M$-1.21B
Gross Margin46.2%56.6%
Operating Margin-315.3%-37.0%
Forward P/E6.0x
Total Debt$282K$2.80B
Cash & Equiv.$1M$170M

INBS vs QDELLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

INBS
QDEL
StockDec 20May 26Return
Intelligent Bio Sol… (INBS)1000.1-99.9%
QuidelOrtho Corpora… (QDEL)1006.0-94.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: INBS vs QDEL

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: QDEL leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Intelligent Bio Solutions Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
INBS
Intelligent Bio Solutions Inc.
The Income Pick

INBS is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 1.91
  • Lower volatility, beta 1.91, Low D/E 10.0%, current ratio 0.77x
  • Beta 1.91, current ratio 0.77x
Best for: income & stability and sleep-well-at-night
QDEL
QuidelOrtho Corporation
The Growth Play

QDEL carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth -1.9%, EPS growth 45.4%, 3Y rev CAGR -5.8%
  • -34.9% 10Y total return vs INBS's -99.9%
  • -1.9% revenue growth vs INBS's -1.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthQDEL logoQDEL-1.9% revenue growth vs INBS's -1.9%
Quality / MarginsQDEL logoQDEL-45.6% margin vs INBS's -315.4%
Stability / SafetyINBS logoINBSBeta 1.91 vs QDEL's 2.59, lower leverage
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)INBS logoINBS+99.1% vs QDEL's -58.3%
Efficiency (ROA)QDEL logoQDEL-20.7% ROA vs INBS's -64.0%, ROIC -13.6% vs -313.0%

INBS vs QDEL — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

INBSIntelligent Bio Solutions Inc.
FY 2025
Other Sales
100.0%$578,642
QDELQuidelOrtho Corporation
FY 2023
Other
100.0%$483M

INBS vs QDEL — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLQDELLAGGINGINBS

Income & Cash Flow (Last 12 Months)

QDEL leads this category, winning 4 of 6 comparable metrics.

QDEL is the larger business by revenue, generating $2.7B annually — 742.0x INBS's $4M. Profitability is closely matched — net margins range from -45.6% (QDEL) to -3.2% (INBS). On growth, INBS holds the edge at +47.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricINBS logoINBSIntelligent Bio S…QDEL logoQDELQuidelOrtho Corpo…
RevenueTrailing 12 months$4M$2.7B
EBITDAEarnings before interest/tax-$11M-$649M
Net IncomeAfter-tax profit-$11M-$1.2B
Free Cash FlowCash after capex-$10M-$75M
Gross MarginGross profit ÷ Revenue+46.2%+56.6%
Operating MarginEBIT ÷ Revenue-3.2%-37.0%
Net MarginNet income ÷ Revenue-3.2%-45.6%
FCF MarginFCF ÷ Revenue-2.7%-2.8%
Rev. Growth (YoY)Latest quarter vs prior year+47.6%-10.5%
EPS Growth (YoY)Latest quarter vs prior year+43.6%-6.1%
QDEL leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

QDEL leads this category, winning 3 of 3 comparable metrics.
MetricINBS logoINBSIntelligent Bio S…QDEL logoQDELQuidelOrtho Corpo…
Market CapShares × price$3M$733M
Enterprise ValueMkt cap + debt − cash$2M$3.4B
Trailing P/EPrice ÷ TTM EPS-0.11x-0.65x
Forward P/EPrice ÷ next-FY EPS est.5.96x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue0.93x0.27x
Price / BookPrice ÷ Book value/share0.43x0.38x
Price / FCFMarket cap ÷ FCF
QDEL leads this category, winning 3 of 3 comparable metrics.

Profitability & Efficiency

QDEL leads this category, winning 6 of 9 comparable metrics.

QDEL delivers a -56.3% return on equity — every $100 of shareholder capital generates $-56 in annual profit, vs $-104 for INBS. INBS carries lower financial leverage with a 0.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to QDEL's 1.46x. On the Piotroski fundamental quality scale (0–9), QDEL scores 6/9 vs INBS's 3/9, reflecting solid financial health.

MetricINBS logoINBSIntelligent Bio S…QDEL logoQDELQuidelOrtho Corpo…
ROE (TTM)Return on equity-103.7%-56.3%
ROA (TTM)Return on assets-64.0%-20.7%
ROICReturn on invested capital-3.1%-13.6%
ROCEReturn on capital employed-189.6%-18.0%
Piotroski ScoreFundamental quality 0–936
Debt / EquityFinancial leverage0.10x1.46x
Net DebtTotal debt minus cash-$738,104$2.6B
Cash & Equiv.Liquid assets$1M$170M
Total DebtShort + long-term debt$281,805$2.8B
Interest CoverageEBIT ÷ Interest expense-174.82x-5.18x
QDEL leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

QDEL leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in QDEL five years ago would be worth $891 today (with dividends reinvested), compared to $23 for INBS. Over the past 12 months, INBS leads with a +99.1% total return vs QDEL's -58.3%. The 3-year compound annual growth rate (CAGR) favors QDEL at -50.4% vs INBS's -58.4% — a key indicator of consistent wealth creation.

MetricINBS logoINBSIntelligent Bio S…QDEL logoQDELQuidelOrtho Corpo…
YTD ReturnYear-to-date-71.0%-62.6%
1-Year ReturnPast 12 months+99.1%-58.3%
3-Year ReturnCumulative with dividends-92.8%-87.8%
5-Year ReturnCumulative with dividends-99.8%-91.1%
10-Year ReturnCumulative with dividends-99.9%-34.9%
CAGR (3Y)Annualised 3-year return-58.4%-50.4%
QDEL leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — INBS and QDEL each lead in 1 of 2 comparable metrics.

INBS is the less volatile stock with a 1.91 beta — it tends to amplify market swings less than QDEL's 2.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. QDEL currently trades 27.6% from its 52-week high vs INBS's 9.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricINBS logoINBSIntelligent Bio S…QDEL logoQDELQuidelOrtho Corpo…
Beta (5Y)Sensitivity to S&P 5001.85x2.28x
52-Week HighHighest price in past year$24.90$38.99
52-Week LowLowest price in past year$0.54$10.22
% of 52W HighCurrent price vs 52-week peak+9.2%+27.6%
RSI (14)Momentum oscillator 0–10036.135.2
Avg Volume (50D)Average daily shares traded86K2.2M
Evenly matched — INBS and QDEL each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricINBS logoINBSIntelligent Bio S…QDEL logoQDELQuidelOrtho Corpo…
Analyst RatingConsensus buy/hold/sellHold
Price TargetConsensus 12-month target$12.25
# AnalystsCovering analysts15
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

QDEL leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.

Best OverallQuidelOrtho Corporation (QDEL)Leads 4 of 6 categories
Loading custom metrics...

INBS vs QDEL: Frequently Asked Questions

8 questions · data-driven answers · updated daily

01

Is INBS or QDEL a better buy right now?

For growth investors, QuidelOrtho Corporation (QDEL) is the stronger pick with -1.

9% revenue growth year-over-year, versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). Analysts rate QuidelOrtho Corporation (QDEL) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — INBS or QDEL?

Over the past 5 years, QuidelOrtho Corporation (QDEL) delivered a total return of -91.

1%, compared to -99. 8% for Intelligent Bio Solutions Inc. (INBS). Over 10 years, the gap is even starker: QDEL returned -34. 6% versus INBS's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — INBS or QDEL?

By beta (market sensitivity over 5 years), Intelligent Bio Solutions Inc.

(INBS) is the lower-risk stock at 1. 85β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 23% more volatile than INBS relative to the S&P 500. On balance sheet safety, Intelligent Bio Solutions Inc. (INBS) carries a lower debt/equity ratio of 10% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

04

Which is growing faster — INBS or QDEL?

By revenue growth (latest reported year), QuidelOrtho Corporation (QDEL) is pulling ahead at -1.

9% versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). On earnings-per-share growth, the picture is similar: Intelligent Bio Solutions Inc. grew EPS 68. 7% year-over-year, compared to 45. 4% for QuidelOrtho Corporation. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — INBS or QDEL?

QuidelOrtho Corporation (QDEL) is the more profitable company, earning -41.

5% net margin versus -346. 2% for Intelligent Bio Solutions Inc. — meaning it keeps -41. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: QDEL leads at -33. 7% versus -348. 7% for INBS. At the gross margin level — before operating expenses — QDEL leads at 46. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Which pays a better dividend — INBS or QDEL?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

07

Is INBS or QDEL better for a retirement portfolio?

For long-horizon retirement investors, Intelligent Bio Solutions Inc.

(INBS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INBS: -99. 9%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

08

What are the main differences between INBS and QDEL?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

INBS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 23%
  • Gross Margin > 27%
Run This Screen
Stocks Like

QDEL

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 33%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform INBS and QDEL on the metrics below

Revenue Growth>
%
(INBS: 47.6% · QDEL: -10.5%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.